Update · Medicare news

Medicare's Negotiated Drug Prices: What Changed in 2026 and What's Next

Medicare's first negotiated prices for 10 drugs, including Eliquis, Jardiance and Xarelto, took effect January 1, 2026. Prices for 15 more, including Ozempic and Wegovy, start January 1, 2027, and the first Part B drugs follow in 2028. What you pay at the pharmacy still depends on your plan.

Person sorting pills beside prescription bottles

In short

  • Ten drugs have Medicare negotiated prices in 2026, set for a 30-day supply and covering drugs for diabetes, heart conditions, blood clots and cancer.
  • Fifteen more drugs, including Ozempic, Rybelsus and Wegovy, get negotiated prices on January 1, 2027. CMS estimates enrollees will pay less out of pocket that year as a result.
  • The third round, announced January 27, 2026, includes the first Part B drugs given in a doctor's office, with prices starting in 2028.
  • A negotiated price is what your plan pays. Your own cost still depends on your plan's deductible, tiers and coinsurance.

Medicare's first negotiated prices for 10 drugs took effect January 1, 2026. A second round starts in January 2027, and a third is underway. Use 2027 plan documents for reviews during the October 15 to December 7, 2026 Open Enrollment Period. Here is what negotiation means for your medications and the questions to check in your own coverage.

What is Medicare drug price negotiation?

Under the Inflation Reduction Act of 2022, Medicare can negotiate prices directly with drugmakers for certain high-cost brand-name drugs. The negotiated price is what Medicare drug coverage pays for a 30-day supply. Your copay is set separately by your plan.

The program runs in rounds. Each round picks a set of drugs, and the agreed prices take effect on January 1 of a later year.

Which drugs got negotiated prices in 2026?

The first 10 prices took effect January 1, 2026. Each is set for a 30-day supply, and CMS lists the price for every drug in its fact sheet.

DrugCommonly used for
JanuviaType 2 diabetes
Fiasp and NovoLogInsulin
FarxigaDiabetes, heart failure, kidney disease
JardianceDiabetes, heart failure
XareltoBlood thinner
EliquisBlood thinner
EntrestoHeart failure
EnbrelRheumatoid arthritis and other conditions
StelaraPsoriasis, Crohn's disease
ImbruvicaBlood cancers

Does a negotiated price lower what you pay?

Sometimes, and it depends on your plan. If you are still in your deductible, or your plan charges coinsurance (a percentage of the drug's cost), a lower price usually lowers your share. If your plan charges a flat copay for that drug, you may see no change at the counter.

Other rules may matter more. Insulin already has its own monthly cap for a one-month supply. And your yearly out-of-pocket spending on covered Part D drugs stops once you reach the 2026 cap. If you were already hitting that cap, a lower price on one drug may not change your yearly total. Our guide to the Part D out-of-pocket cap explains what counts.

What changes on January 1, 2027?

Fifteen more drugs get negotiated prices. CMS estimates people with Medicare will pay less out of pocket in 2027 as a result. The 2027 drugs are:

  • Ozempic, Rybelsus and Wegovy
  • Trelegy Ellipta
  • Breo Ellipta
  • Linzess
  • Tradjenta
  • Janumet and Janumet XR
  • Vraylar
  • Xifaxan
  • Otezla and Otezla XR
  • Austedo and Austedo XR
  • Ofev
  • Xtandi
  • Ibrance
  • Calquence
  • Pomalyst

CMS publishes the negotiated price for a 30-day supply of each drug in its 2027 fact sheet. The 2027 Part D rules are also set. Both the maximum deductible and the out-of-pocket cap go up, and Medicare.gov lists the new limits. A drug's negotiated price does not tell you its tier or copay on a 2027 plan. That comes from each plan's formulary, the list of drugs it covers.

What about Wegovy and the GLP-1 Bridge?

The Medicare GLP-1 Bridge, which started July 1, 2026, is separate from negotiation. It lets people who qualify get Wegovy, Zepbound KwikPen or Foundayo for weight management at a flat monthly cost, regardless of income. In April, CMS extended it through December 31, 2027.

To qualify, you must be 18 or older, have Part D coverage, have a body mass index in set ranges (35 or higher, or lower with certain heart, blood vessel, blood pressure, kidney or prediabetes conditions), and get a prior approval form from your prescriber. People with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease are not eligible for the Bridge. That monthly payment does not count toward your deductible or yearly cap. Talk to your doctor about whether any of these drugs is right for you.

What comes after 2027?

On January 27, 2026, CMS named 15 drugs for the third round, with prices starting in 2028. For the first time, the list includes Part B drugs, the kind given in a doctor's office or clinic. The list includes Trulicity, Biktarvy, Orencia, Cosentyx, Erleada, Kisqali, Entyvio, Verzenio, Botox, Lenvima, Xolair, Rexulti, Xeljanz, Anoro Ellipta and Cimzia. Tradjenta was picked for renegotiation.

Part B drugs matter for people on Original Medicare, who generally pay 20% coinsurance on them unless a Medicare Supplement plan covers it.

What should you do this fall?

  1. Write down every medication, with the dose and how often you take it.
  2. Check whether any of them are on the 2026 or 2027 lists above.
  3. If you already have a drug plan, read its Annual Notice of Change alongside its 2027 coverage documents.
  4. Compare 2027 Part D plans on total yearly cost for your medication list and pharmacy, not just premium.
  5. If money is tight, check whether you qualify for Extra Help.

For the rest of this year's numbers, see how 2026 Medicare costs work. For unbiased help, call 1-800-MEDICARE (1-800-633-4227), 24 hours a day, 7 days a week (TTY 1-877-486-2048), or Nebraska SHIP (formerly SHIIP) at 1-800-234-7119.

Frequently asked questions

Ten Part D drugs: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and the insulins Fiasp and NovoLog. Their negotiated prices took effect January 1, 2026, and CMS lists each one in its fact sheet. These are prices Medicare drug coverage pays. The copay you see at the pharmacy depends on your plan.

Yes. Ozempic, Rybelsus and Wegovy share one negotiated price for a 30-day supply starting January 1, 2027. They are part of the second group of 15 drugs. Your own cost will still depend on how your 2027 plan covers the drug, including its deductible and tier. Separately, the Medicare GLP-1 Bridge offers Wegovy for weight loss at a flat monthly cost to people who qualify, through December 31, 2027.

It can, but not always. If you are paying the full price during your deductible, or your plan charges a percentage of the drug's cost, a lower price usually means you pay less. If your plan charges a flat copay for the drug, your copay may not change. Your total out-of-pocket drug spending is also capped each year, and CMS raised that cap for 2027.

Yes, for drug coverage. The negotiated prices apply to covered Part D drugs, whether you get Part D through a standalone drug plan or through a Medicare Advantage plan that includes drug coverage. They do not apply if you have no Part D coverage. Starting in 2028, the third round also sets prices for some Part B drugs that are given in a doctor's office or clinic.

In 2028. On January 27, 2026, CMS picked 15 drugs for the third round, and for the first time the list includes Part B drugs, which are usually given by a doctor or clinic. The 15 drugs include Trulicity, Biktarvy, Orencia, Entyvio and Botox, among others. The diabetes drug Tradjenta was also selected for renegotiation. Prices from this round take effect in 2028.

Sources

  1. CMS: Negotiated prices for initial price applicability year 2026 (fact sheet) (opens in a new tab)
  2. CMS: Negotiated prices for initial price applicability year 2027 (fact sheet) (opens in a new tab)
  3. CMS: Selected drug list for initial price applicability year 2028 (fact sheet) (opens in a new tab)
  4. Medicare.gov: Medicare GLP-1 Bridge (CMS Product No. 12234) (opens in a new tab)
  5. CMS: Status update on the GLP-1 Bridge and BALANCE Model for CY 2027 (April 21, 2026) (opens in a new tab)
  6. CMS: CY 2027 Medicare Advantage and Part D Rate Announcement (opens in a new tab)
  7. Medicare.gov: Understanding Medicare Advantage and Medicare drug plan enrollment periods (opens in a new tab)
Bill Jurey

Bill Jurey

Independent Licensed Insurance Agent · Lincoln, Nebraska

Bill spent twenty years on manufacturing floors before getting licensed in 2017. He has helped Nebraskans with Medicare since 2020, shopping several carriers so clients get straight answers instead of a sales pitch. More about Bill

The following representation figures apply to Lancaster County, Nebraska. Representation and plan availability vary by county. We do not offer every plan available in your area. Currently we represent 4 organizations which offer 28 products in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options. 1-800-MEDICARE (1-800-633-4227) is available 24 hours a day, 7 days a week. TTY users can call 1-877-486-2048.

Talk to Bill

Want a straight answer about your situation?

Bring your medications and your doctors. I will lay out your options in plain English, and you decide. My help costs you nothing, and there is never any pressure.

In person in Lincoln, by phone, or by video. By appointment.

Portrait of Bill Jurey